MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

AbbVie Inc

Отворен

СекторЗдравеопазване

185.11 2.66

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

178.98

Максимум

186.19

Ключови измерители

By Trading Economics

Приходи

-1.6B

-23M

Продажби

642M

15B

P/E

Средно за сектора

71.496

57.333

EPS

2.16

Дивидентна доходност

3.86

Марж на печалбата

-0.152

Служители

55,000

EBITDA

-4.4B

535M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+17.54% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.86%

2.63%

Следващи печалби

25.04.2025 г.

Следваща дата на дивидент

15.05.2025 г.

Следваща дата на екс-дивидент

14.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-29B

306B

Предишно отваряне

182.45

Предишно затваряне

185.11

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

AbbVie Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.04.2025 г., 18:18 ч. UTC

Значими двигатели на пазара

Pharma Shares Reverse Losses After Tariff Pause

9.04.2025 г., 09:39 ч. UTC

Значими двигатели на пазара

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

27.02.2025 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12.02.2025 г., 13:41 ч. UTC

Значими двигатели на пазара

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

31.01.2025 г., 13:28 ч. UTC

Печалби

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

14.03.2025 г., 09:30 ч. UTC

Топ новини

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3.03.2025 г., 15:04 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6.02.2025 г., 13:25 ч. UTC

Топ новини
Печалби

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6.02.2025 г., 12:00 ч. UTC

Печалби

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5.02.2025 г., 12:00 ч. UTC

Топ новини

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31.01.2025 г., 15:50 ч. UTC

Топ новини
Печалби

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31.01.2025 г., 13:51 ч. UTC

Печалби

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

31.01.2025 г., 13:47 ч. UTC

Топ новини
Печалби

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31.01.2025 г., 13:24 ч. UTC

Пазарно говорене
Печалби

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

31.01.2025 г., 12:46 ч. UTC

Печалби

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

31.01.2025 г., 12:39 ч. UTC

Печалби

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

31.01.2025 г., 12:38 ч. UTC

Печалби

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

31.01.2025 г., 12:38 ч. UTC

Печалби

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

31.01.2025 г., 12:37 ч. UTC

Печалби

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

31.01.2025 г., 12:37 ч. UTC

Печалби

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Loss $22M >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q International HUMIRA Rev $436M >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Adj EPS $2.16 >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

31.01.2025 г., 12:36 ч. UTC

Печалби

AbbVie 4Q Loss/Shr 2c >ABBV

Сравнение с други в отрасъла

Ценова промяна

AbbVie Inc Прогноза

Ценова цел

By TipRanks

17.54% нагоре

12-месечна прогноза

Среден 212 USD  17.54%

Висок 241 USD

Нисък 190 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за AbbVie Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

18 ratings

13

Купи

5

Задържане

0

Продай

Техническа оценка

By Trading Central

174.2 / 180.5Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.